Abstract: Objective: The treatment of henoch-Schönlein purpura (HSP) with moderate proteinuria remains controversial. We retrospectively analyzed the efficacy of immune suppressants, with a particular emphasis on mycophenolate mofetil (MMF). Methods: Ninety-five HSP patients with moderate proteinuria (1.0–3.5 g/24 h) after at least three months of therapy with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) were divided into three groups: an MMF group (n=33) that received MMF 1.0–1.5 g/d combined with prednisone (0.4–0.5 mg/(kg·d)), a corticosteroid (CS) group (n=31) that received full-dose prednisone (0.8–1.0 mg/(kg·d)), and a control group (n=31). Patients in the MMF and CS groups continued to take ACEI or ARB at the original dose. The patients in the control group continued to take ACEI or ARB but the dose was increased by (1.73±0.58)-fold. The patients were followed up for 6–78 months (median 28 months). Results: The baseline proteinuria was higher in the MMF group ((2.1±0.9) g/24 h) than in the control group ((1.6±0.8) g/24 h) (P=0.039). The proteinuria decreased significantly in all groups during follow-up, but only in the MMF group did it decrease significantly after the first month. At the end of follow-up, the proteinuria was (0.4±0.7) g/24 h in the MMF group and (0.4±0.4) g/24 h in the CS group, significantly lower than that in the control group ((0.9±1.1) g/24 h). The remission rates in the MMF group, CS group, and control group were respectively 72.7%, 71.0%, and 48.4% at six months and 72.7%, 64.5%, and 45.2% at the end of follow-up. The overall number of reported adverse events was 17 in the MMF group, 30 in the CS group, and 6 in the control group (P<0.001). Conclusions: MMF with low-dose prednisone may be as effective as full-dose prednisone and tend to have fewer adverse events. Therefore, it is probably superior to conservative treatments of adult HSP patients with moderate proteinuria.

霉酚酸酯联合糖皮质激素诱导治疗过敏性紫癜性肾炎的回顾性研究

[1]Chan, T.M., Li, F.K., Tang, C.S., et al., 2000. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med., 343(16):1156-1162.

[2]Coppo, R., Mazzucco, G., Cagnoli, L., et al., 1997. Long-term prognosis of Henoch-Schönlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schönlein purpura. Nephrol. Dial. Transplant., 12(11):2277-2283.

[3]Coppo, R., Andrulli, S., Amore, A., et al., 2006. Predictors of outcome in Henoch-Schönlein nephritis in children and adults. Am. J. Kidney Dis., 47(6):993-1003.

[4]Counahan, R., Winterborn, M.H., White, R.H., et al., 1977. Prognosis of Henoch-Schönlein nephritis in children. Br. Med. J., 2(6078):11-14.

[5]Du, Y., Hou, L., Zhao, C., et al., 2012. Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil. Pediatr. Nephrol., 27(5):765-771.

[6]Foster, B.J., Bernard, C., Drummond, K.N., et al., 2000. Effective therapy for severe Henoch-Schönlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. J. Pediatr., 136(3):370-375.

[7]Ginzler, E.M., Dooley, M.A., Aranow, C., et al., 2005. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med., 353(21):2219-2228.

[8]Han, F., Liu, G., Zhang, X., et al., 2011. Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis. Am. J. Nephrol., 33(2):185-192.

[9]Hu, W., Liu, C., Xie, H., et al., 2008. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol. Dial. Transplant., 23(4):1307-1312.

[10]Huber, A.M., King, J., McLaine, P., et al., 2004. A randomized, placebo-controlled trial of prednisone in early Henoch Schonlein Purpura. BMC Med., 2(1):7.

[11]Kawasaki, Y., Suzuki, J., Suzuki, H., 2004. Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schöenlein nephritis: a clinical and histopathological study. Nephrol. Dial. Transplant., 19(4):858-864.

[12]KDIGO (Kidney Disease: Improving Global Outcomes) Glomerulonephritis Work Group, 2012. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. Suppl., 2(2):139-274.

[13]Kellerman, P.S., 2006. Henoch-Schönlein purpura in adults. Am. J. Kidney Dis., 48(6):1009-1016.

[14]Mollica, F., Li, V.S., Garozzo, R., et al., 1992. Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura. Eur. J. Pediatr., 151(2):140-144.

[15]Nikibakhsh, A.A., Mahmoodzadeh, H., Karamyyar, M., et al., 2010. Treatment of complicated Henoch-Schönlein purpura with mycophenolate mofetil: a retrospective case series report. Int. J. Rheumatol., 2010:254316.

[16]Oh, H.J., Ahn, S.V., Yoo, D.E., et al., 2012. Clinical outcomes, when matched at presentation, do not vary between adult-onset Henoch-Schönlein purpura nephritis and IgA nephropathy. Kidney Int., 82(12):1304-1312.

[17]Ozen, S., Ruperto, N., Dillon, M.J., et al., 2006. EULAR/PreS endorsed consensus criteria for the classification of childhood vasculitides. Ann. Rheum. Dis., 65(7):936-941.

[18]Pillebout, E., Thervet, E., Hill, G., et al., 2002. Henoch-Schönlein Purpura in adults: outcome and prognostic factors. J. Am. Soc. Nephrol., 13(5):1271-1278.

[19]Pillebout, E., Alberti, C., Guillevin, L., et al., 2010. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schonlein Purpura. Kidney Int., 78(5):495-502.

[20]Ren, P., Han, F., Chen, L., et al., 2012. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis. Am. J. Nephrol., 36(3):271-277.

[21]Ronkainen, J., Nuutinen, M., Koskimies, O., 2002. The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study. Lancet, 360(9334):666-670.

[22]Ronkainen, J., Koskimies, O., Ala-Houhala, M., et al., 2006. Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J. Pediatr., 149(2):241-247.

[23]Saulsbury, F.T., 1993. Corticosteroid therapy does not prevent nephritis in Henoch-Schönlein purpura. Pediatr. Nephrol., 7(1):69-71.

[24]Shenoy, M., Bradbury, M.G., Lewis, M.A., et al., 2007. Outcome of Henoch-Schönlein purpura nephritis treated with long-term immunosuppression. Pediatr. Nephrol., 22(10):1717-1722.

[25]Tang, S.C., Tang, A.W., Wong, S.S., et al., 2010. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int., 77:543-759.

[26]Weiss, P.F., Feinstein, J.A., Luan, X., et al., 2007. Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review. Pediatrics, 120(5):1079-1087.